Weerapong Phumratanaprapin
Overview
Explore the profile of Weerapong Phumratanaprapin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
486
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jittamala P, Boyd S, Schilling W, Watson J, Ngamprasertchai T, Siripoon T, et al.
EClinicalMedicine
. 2025 Feb;
80:103036.
PMID: 39896880
Background: The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine were repurposed for the treatment of early COVID-19 based on their antiviral activity , and observational and clinical trial evidence...
2.
Schilling W, Mukaka M, Callery J, Llewelyn M, Cruz C, Dhorda M, et al.
PLoS Med
. 2024 Sep;
21(9):e1004428.
PMID: 39264960
Background: Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials...
3.
Wongnak P, Schilling W, Jittamala P, Boyd S, Luvira V, Siripoon T, et al.
Lancet Infect Dis
. 2024 Apr;
24(9):953-963.
PMID: 38677300
Background: Effective antiviral drugs prevent hospitalisation and death from COVID-19. Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 clearance estimated from serial viral genome densities...
4.
Luvira V, Schilling W, Jittamala P, Watson J, Boyd S, Siripoon T, et al.
BMC Infect Dis
. 2024 Jan;
24(1):89.
PMID: 38225598
Background: Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir has been recommended for the treatment of COVID-19 in some...
5.
Sriboonvorakul N, Chotivanich K, Silachamroon U, Phumratanaprapin W, Adams J, Dondorp A, et al.
PLoS Pathog
. 2023 Oct;
19(10):e1011661.
PMID: 37856470
The pathophysiology of severe falciparum malaria involves a complex interaction between the host, parasite, and gut microbes. In this review, we focus on understanding parasite-induced intestinal injury and changes in...
6.
Schilling W, Jittamala P, Watson J, Boyd S, Luvira V, Siripoon T, et al.
Lancet Infect Dis
. 2023 Oct;
24(1):36-45.
PMID: 37778363
Background: Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral treatments, but their antiviral activities in patients have not been compared directly. The aim of this ongoing platform...
7.
Jittamala P, Schilling W, Watson J, Luvira V, Siripoon T, Ngamprasertchai T, et al.
J Infect Dis
. 2023 Jul;
228(10):1318-1325.
PMID: 37470445
Background: Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods: In a multicenter open-label, controlled, adaptive, pharmacometric platform trial,...
8.
Chancharoenthana W, Kamolratanakul S, Leelahavanichkul A, Ariyanon W, Chinpraditsuk S, Saelim R, et al.
World J Gastroenterol
. 2023 Jun;
29(19):3013-3026.
PMID: 37274795
Background: Prolonged symptoms after corona virus disease 2019 (Long-COVID) in dialysis-dependent patients and kidney transplant (KT) recipients are important as a possible risk factor for organ dysfunctions, especially gastrointestinal (GI)...
9.
Omar F, Phumratanaprapin W, Silachamroon U, Hanboonkunupakarn B, Sriboonvorakul N, Thaipadungpanit J, et al.
Trop Med Infect Dis
. 2023 Mar;
8(3).
PMID: 36977148
Tropical acute febrile illness (TAFI) is one of the most frequent causes of acute kidney injury (AKI). The prevalence of AKI varies worldwide because there are limited reports available and...
10.
Schilling W, Jittamala P, Watson J, Ekkapongpisit M, Siripoon T, Ngamprasertchai T, et al.
Elife
. 2023 Feb;
12.
PMID: 36803992
Background: There is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it...